608 related articles for article (PubMed ID: 35038344)
1. Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG.
Katz MJ; Heaney CD; Pisanic N; Smith L; Bigelow BF; Sheikh F; Boudreau A; Kruczynski K; Hsu YJ; Salinas AB; Cosgrove SE; Rock C
J Am Geriatr Soc; 2022 Mar; 70(3):659-668. PubMed ID: 35038344
[TBL] [Abstract][Full Text] [Related]
2. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
4. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
[TBL] [Abstract][Full Text] [Related]
5. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents.
Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC
J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651
[TBL] [Abstract][Full Text] [Related]
6. Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses.
Pisanic N; Antar AAR; Kruczynski KL; Gregory Rivera M; Dhakal S; Spicer K; Randad PR; Pekosz A; Klein SL; Betenbaugh MJ; Detrick B; Clarke W; Thomas DL; Manabe YC; Heaney CD
J Immunol Methods; 2023 Mar; 514():113440. PubMed ID: 36773929
[TBL] [Abstract][Full Text] [Related]
7. Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity.
Thomas SN; Karger AB; Altawallbeh G; Nelson KM; Jacobs DR; Gorlin J; Barcelo H; Thyagarajan B
Sci Rep; 2022 May; 12(1):8890. PubMed ID: 35614113
[TBL] [Abstract][Full Text] [Related]
8. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines.
Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA
Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108
[No Abstract] [Full Text] [Related]
9. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
10. Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study.
Meyers E; Deschepper E; Duysburgh E; De Rop L; De Burghgraeve T; Van Ngoc P; Digregorio M; Delogne S; Coen A; De Clercq N; Buret L; Coenen S; Sutter A; Scholtes B; Verbakel JY; Cools P; Heytens S
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366456
[TBL] [Abstract][Full Text] [Related]
11. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
12. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.
Pierobon A; Zotto AD; Antico A; De Antoni ME; Vianello L; Gennari M; Di Caprio A; Russo F; Brambilla G; Saugo M
Clin Microbiol Infect; 2022 Apr; 28(4):614.e5-614.e7. PubMed ID: 34958917
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020-2022.
Inoue W; Kimura Y; Okamoto S; Nogimori T; Sakaguchi-Mikami A; Yamamoto T; Tsunetsugu-Yokota Y
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543812
[TBL] [Abstract][Full Text] [Related]
14. Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.
Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Delpui V; Si-Mohamed N; Niel C; Rolland Y; Montes B; Groc S; Rafasse S; Dupuy AM; Gros N; Muriaux D; Picot MC; Bousquet J
Allergy; 2022 Jun; 77(6):1885-1894. PubMed ID: 34652831
[TBL] [Abstract][Full Text] [Related]
15. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents.
Torres I; Albert E; Giménez E; Alcaraz MJ; Botija P; Amat P; Remigia MJ; Beltrán MJ; Rodado C; Huntley D; Olea B; Navarro D
Clin Microbiol Infect; 2021 Nov; 27(11):1672-1677. PubMed ID: 34174397
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.
Soeorg H; Jõgi P; Naaber P; Ottas A; Toompere K; Lutsar I
Infect Dis (Lond); 2022 Jan; 54(1):63-71. PubMed ID: 34520315
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
Meyers E; De Rop L; Deschepper E; Duysburgh E; De Burghgraeve T; Van Ngoc P; Digregorio M; Delogne S; Coen A; De Clercq N; Buret L; Coenen S; De Sutter A; Scholtes B; Verbakel JY; Cools P; Heytens S
Eur J Gen Pract; 2023 Dec; 29(2):2149732. PubMed ID: 36440533
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal serologic and viral testing post-SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort-Georgia, October 2020‒April 2021.
Tobolowsky FA; Waltenburg MA; Moritz ED; Haile M; DaSilva JC; Schuh AJ; Thornburg NJ; Westbrook A; McKay SL; LaVoie SP; Folster JM; Harcourt JL; Tamin A; Stumpf MM; Mills L; Freeman B; Lester S; Beshearse E; Lecy KD; Brown LG; Fajardo G; Negley J; McDonald LC; Kutty PK; Brown AC;
PLoS One; 2022; 17(10):e0275718. PubMed ID: 36301805
[TBL] [Abstract][Full Text] [Related]
19. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.
Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A
Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935
[TBL] [Abstract][Full Text] [Related]
20. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
